SeekIn Presents New Data Supporting its Pan-cancer Early Detection Test at the Early Detection of Cancer Conference 2022
The large case-control study demonstrates that SeekInCare® has 68.0% sensitivity at 98.0% specificity in 27 different cancer types as a whole. In both retrospective and prospective studies, the solid performance of SeekInCare® puts it into best-in-class category of multi-cancer early detection (MCED) test. SHENZHEN, China, Oct. 19, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection...
Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults
-- Levels of neutralizing antibodies generated by PTX-COVID19-B were non-inferior to Comirnaty®---- PTX-COVID19-B was well tolerated with no safety signals---- Everest is filing IND applications for phase 3 clinical trials for booster indication-- SHANGHAI, Oct. 19, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address...
WeTrade Group to Increase Presence in the Health Market
BEIJING, Oct. 19, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), a global diversified "software as a service" ("SaaS") technology service provider which is committed to providing technical support and digital transformation tools for enterprises across different industries, today announced the development plan (the "Plan") of the Company's global public health business sector Y-Health, to...
Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated Results indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, supporting continued clinical development Additional data presented by Brii's licensing partners at IDWeek 2022 showcase breadth of Company's infectious disease program, spanning six therapeutic...
EDAN Forays into Molecular Point-of-Care Market with Its First-Ever Molecular Diagnostics Solution Released at Medlab Asia 2022
Developed based on Loop-Mediated Isothermal Amplification (LAMP), the new molecular diagnostics analysis system, ClariLight CL30, gives on-the-spot results and empowers physicians for early infectious disease diagnostics because of its agility, fast and flexibility. BANGKOK, Thailand, Oct. 19, 2022 /PRNewswire/ -- EDAN Instruments, Inc. (300206.SZ) showcased its first molecular diagnostics analysis system, ClariLight CL30, at Medlab Asia & Asia Health...
Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on October 26 at 10:00 CEST
GOTHENBURG, Sweden, Oct. 19, 2022 /PRNewswire/ -- Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson. To register for the presentation of the interim report for the period July - September 2022, which will be held on October 26 at 10:00 CEST,...
Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences
Sirnaomics Chief Technology Officer Dmitry Samarsky is a featured speaker at the RNA Leaders USA Congress and 18th Drug Discovery Innovation Programme Gaithersburg, Md. and Suzhou, China, Oct. 19, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK) a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the...
PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL
F-18 Pivalate PET shows high uptake regardless of origin of primary tumour F-18 Pivalate can be used to monitor cerebral metastases Patients without previous external beam radiation show higher tumour uptake, while those previously treated show a trend towards lower uptake MELBOURNE, Australia, Oct. 19, 2022 /PRNewswire/ --...
ONESOLUTION expends her IOT solution into Dental Care Market
ONESOLUTION™ and BRUSHEVA™ Engagement HONG KONG, Oct. 19, 2022 /PRNewswire/ -- ONESOLUTION INNOTECH LTD, the fully owned subsidiary of King Resources, Inc. (OTC: KRFG), the Brand and Distribution network maker of IOT products and services, today announced the extension of the product line through a new sole distribution agreement with BRUSHEVA™, Brusheva was founded by dentists concerned about the...
MedAlliance to be Acquired by Cordis
GENEVA, Oct. 19, 2022 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has announced it has entered into an agreement with Cordis for an acquisition which includes an initial investment of $35M and upfront closing payment of $200M, regulatory achievement milestones of up to $125M and commercial milestones of up to $775M through 2029...
